Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

About Illumina’s acquisition

November 2, 2018 0

Illumina (ILMN) and Pacific Biosciences (PACB) announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a …

About Exelixis

November 2, 2018 0

Exelixis (EXEL) provided an update that testified to its solid fundamentals, the growth of its approved …

About the Celyad/Horizon discovery agreement

November 1, 2018 0

Celyad (CYAD) announced an exclusive agreement with Horizon Discovery Group plc, for the use of its shRNA …

Observing Array Biopharma

October 31, 2018 0

A number of biotech or biopharmaceutical companies have succeeded in the past couple of years in …

We call it the bad market

October 30, 2018 0

The Week in Review #33 WE CALL IT THE BAD MARKET The Federal Reserve’s raising of …

Prenatal gene editing has already been performed in laboratory animals

October 26, 2018 0

Although the tests are for the prevention of a life-threatening metabolic disorder, the prenatal animal testing …

Alleviating osteoarthritis pain without the need for opioid drugs

October 25, 2018 0

Tanezumab, an investigational humanized monoclonal antibody developed by Pfizer (PFE) and Eli Lilly (LLY), met all …

Immunotherapy and some other results from ESMO 2018

October 24, 2018 0

IMMUNOTHERAPY The Checkpoint Inhibitors The most revered news was the discovery of the checkpoint proteins on …

Positive News

October 22, 2018 0

The Week in Review #32 POSITIVE NEWS PROTEOSTASIS THERAPEUTICS Cystic Fibrosis Two days ago, a clinical-stage …

Why Portola’s stock decline

October 17, 2018 2

Why Portola’s Stock Decline Everybody interested in Portola (PTLA) knows by now that this firm has managed …

Why VTV Therapeutics’ stock added over 48% to its price before trading hours today

October 17, 2018 0

VTV Therapeutics’ (VTVT) stock price added over 48% before trading hours today. The news that some …

After being approved for Eczema, Regeneron’s and Sanofi’s product, Dupixent, succeeded in treating chronic rhinosinusitis, nasal polyps and asthma.

October 16, 2018 0

In two pivotal Phase 3 placebo-controlled trials Regeneron Pharmaceuticals’ (REGN) and Sanofi’s (SNY) drug, Dupixent® (dupilumab), demonstrated a …

Amgen’s product Amgevita, a biosimilar to adalimumab, will be launched in the European market today.

October 16, 2018 0

Amgen (AMGN) announced that AmgevitaTM, a biosimilar to adalimumab, will launch in markets across Europe beginning on October 16, …

Following the Stars. Less Science and More Logic

October 14, 2018 0

Prohost Letter #424 Following the Stars Less Science and More Logic We reiterate that while a …

$Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated thyroid cancer (DTC) patients$

Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated thyroid cancer (DTC) patients

October 9, 2018 0

Exelixis (EXEL) announced its initiation of a phase 3 pivotal trial (COSMIC-311) of Cabometyx (cabozantinib) in patients …

Spark Therapeutics: An encouraging attempt to dethrone enzyme replacement as the standard of care treatment for Pompe Disease.

October 9, 2018 0

On Saturday, October 6, 2018, Spark Therapeutics (ONCE) presented positive data from a preclinical trial with SPK-3006 …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

About Illumina’s acquisition

About Exelixis

About the Celyad/Horizon discovery agreement

Observing Array Biopharma

We call it the bad market

Prenatal gene editing has already been performed in laboratory animals

Alleviating osteoarthritis pain without the need for opioid drugs

Immunotherapy and some other results from ESMO 2018

Positive News

Why Portola’s stock decline

Why VTV Therapeutics’ stock added over 48% to its price before trading hours today

After being approved for Eczema, Regeneron’s and Sanofi’s product, Dupixent, succeeded in treating chronic rhinosinusitis, nasal polyps and asthma.

Amgen’s product Amgevita, a biosimilar to adalimumab, will be launched in the European market today.

Following the Stars. Less Science and More Logic

Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated thyroid cancer (DTC) patients

Spark Therapeutics: An encouraging attempt to dethrone enzyme replacement as the standard of care treatment for Pompe Disease.

Today’s Highlighted news is from …

PTC Therapeutics: Solid data from its oral product Risdiplam in spinal muscular atrophy

The FDA granted Paratek two important product approvals. One is for acne

Outperformance, Underperformance and Volatility